In a recent interview at the SNMMI conference, Roger Lecomte, Ph.D., and Vincent Doyon discussed the advent of ultra-high resolution (UHR) brain positron emission tomography (PET), which reportedly offers double the spatial resolution of conventional PET and may facilitate earlier detection of Alzheimer’s disease and other conditions.
Emphasizing pixelated detectors and an isotropic spatial resolution upward of 1.25 mm, ultra-high resolution (UHR) brain positron emission tomography (PET) represents a significant advance that provides improved characterization and quantification of brain regions that could not be seen with whole-body PET, noted Roger Lecomte, Ph.D., during a recent interview at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference.
“The spatial resolution is a factor of two better than HRRT (High Resolution Research Tomograph) and a factor of three better than any clinical scanners today. It’s a quantum leap in terms of spatial resolution,” said Dr. Lecomte, a professor of nuclear medicine and radiobiology at the University of Sherbrooke in Quebec, Canada. “To image the brain where you have small structures in the cortex, the brain stem and different regions of the brain, spatial resolution is very important to be able to detect the uptake of radiotracers in very tiny structures.”
One of the areas of improvement with UHR PET imaging was the enhanced visualization of the subfields of the hippocampus that can play a role in the progression of Alzheimer’s disease, according to Vincent Doyon, who presented some of the preliminary findings with UHR PET at the SNMMI conference.
“Depending on how these subfields are affected in the disease, we can see whether treatments are effective for the patient,” added Doyon, a master’s student in the Department of Radiation Sciences and Biomedical Imaging at the University of Sherbrooke.
Donyon added that UHR PET offers enhanced visualization of brainstem nuclei, including raphe nuclei, that may aid in the diagnosis and treatment of a variety of neuropsychiatric conditions, including schizophrenia, depression, and anxiety disorders.
For other insights from Dr. Lecomte and Mr. Doyon, watch the video below.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
CT Perfusion Study Shows Enhanced Detection of Medium Vessel Occlusions with Emerging AI Software
May 21st 2025The Rapid CTP AI software offered 23 percent greater detection of medium vessel occlusions in comparison to the Viz CTP AI software, according to research presented at the European Stroke (Organization) Conference (ESOC).
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.